title: Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study.
abstract: Bullous pemphigoid (BP) has been reported to be associated with significant morbidities and a considerable mortality rate. We retrospectively studied 94 patients with BP in a Chinese tertiary medical center between 2005 and 2010 to evaluate the treatment of BP and prognostic factors for the mortality of BP. Cerebrovascular diseases (42.55%) and hypertension (39.36%) were the most common pre-existing conditions. Cardiopathy, diabetes and psoriasis pre-existed in 24.47%, 22.34% and 5.32%, respectively. Eighty of all 94 patients were treated by systemic corticosteroid at prednisone 0.3 mg/kg to 1.5 mg/kg daily. Patients were followed up for a minimum of 1 year or until the time of death. The mean duration of follow-up was 32 months. Kaplan-Meier analysis showed a 1-year survival probability of 76.6% (standard error 4.4%), with a 95% confidence interval (68.04%, 85.16%). Multivariate analysis revealed that increased age, bedridden condition, presence of cerebrovascular diseases at diagnosis, pre-existing cardiopathy and low serum albumin level were associated with the elevated 1-year mortality rate of BP.
authors: Department of Dermatology, The First Affiliated Hospital of China Medical University, 155 North Nanjing Street, Shenyang 110001, China.
authors: Li-Ming
authors: LM
authors: Zhang
authors: Jian
authors: J
authors: Wu
authors: Ting
authors: T
authors: Xiao
authors: Guang-Yu
authors: GY
authors: Jin
authors: Jiu-Hong
authors: JH
authors: Li
authors: Long
authors: L
authors: Geng
authors: Chun-Di
authors: CD
authors: He
authors: Xing-Hua
authors: XH
authors: Gao
authors: Hong-Duo
authors: HD
authors: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications; D002681:China; D048909:Diabetes Complications / Q000150:complications; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D011565:Psoriasis / Q000150:complications; D012189:Retrospective Studies; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D012709:Serum Albumin; D008911:Minocycline; D011241:Prednisone
keywords: bullous pemphigoid; cerebrovascular disease; corticosteroid; mortality; prognosis